FENC
Fennec Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FENC
Fennec Pharmaceuticals Inc.
A company that developing Sodium Thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients
PO Box 13628, 68 TW Alexander Drive , Research Triangle Park, NC 27709
--
Fennec Pharmaceuticals Inc., originally established as a British Columbia company under the name "Sticky" Technologies, changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxyquit Corporation (" Oxide ") and Fennec Pharmaceuticals, and a Canadian company in Canada (" CBI "), collectively referred to here as the "Company", is a biopharmaceutical company with a product in development for the treatment of cancer. The Company is a biopharmaceutical company focused on the development of sodium thiosulfate (" STS ") to prevent the toxicity of platinum poisoning in pediatric cancer patients.
Earnings Call
Q1/2025
Estimate EPS-0.09
Actual EPS-0.04
Estimate Revenue8.18M
Actual Revenue8.75M
Fennec Pharmaceuticals' Q1 2025: Unpacking Key Contradictions in PEDMARK Performance and Financial Outlook
May 20,2025 12:01
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.03
Actual EPS-0.11
Estimate Revenue9.56M
Actual Revenue9.65M
Fennec Pharmaceuticals Q2 2025: Unpacking Key Contradictions in Patient Adherence, Production Timelines, and Market Strategies
Aug 14,2025 05:23
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
FENC has released its 2025 Q3 earnings. EPS was reported at -0.02, versus the expected -0.03, beating expectations. The chart below visualizes how FENC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FENC has released its 2025 Q3 earnings report, with revenue of 12.46M, reflecting a YoY change of 78.69%, and net profit of -638.00K, showing a YoY change of 88.88%. The Sankey diagram below clearly presents FENC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
